enrolment – Page 10 – Communicable Diseases Research

Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis

Original Article

Published on 2021-06-152022-10-30
Journal: Neurological Sciences [Category] Coronavirus, COVID19(2023년), MERS, SARS,

Partner-delivered HIV self-test kits with and without financial incentives in antenatal care and index patients with HIV in Malawi: a three-arm, cluster-randomised controlled trial

Articles

Published on 2021-06-152022-10-30
Journal: The Lancet. Global health [Category] COVID-19,

[키워드] 95% CI adjusted administration ANC antenatal care approach ART assigned Cluster Clusters Cohort computer-generated Contact Controlled trial diagnosed Diagnosis distribution eligible eligible patient enrolment finding funding geometric Government Health HIV HIV testing identify IMPROVE incidence rate initiative intention to treat Intervention lockdowns male nine occurred offered offset Open-label Patient patients patients with HIV Pragmatic Pregnancy Primary outcome proportion random Randomly receiving recruited Registered reported resulting risk secondary significantly more standard care standard care group Standard of care tested the mean Trial with HIV women
[DOI] 10.1016/S2214-109X(21)00175-3 PMC 바로가기 [Article Type] Articles

Safety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: A structured summary of a study protocol for a randomized controlled trial

COVID-19의 장기적인 영향에 대한 아유르베다 중재 및 요가의 안전성 및 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-06-032022-09-10
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 Acute coronary syndrome acute respiratory distress acute respiratory distress syndrome Adverse Adverse drug reaction Agastya Agastya Haritaki alcoholism ARDS Arm arrhythmia Ashwagandha Atrial fibrillation Ayurveda baseline biochemical blinded Blinding calculated Care CBC change chronic respiratory disease clinical clinical assessment Clinical Management Protocol comparator completion Computed tomography conducted confidence confidence level coronary syndrome COVID 19 COVID-19 COVID-19 case Critically ill Critically ill patient critically ill patients CTRI D-dimer depressive diabetes Diabetes Mellitus diagnosed Diego disease dropout rate drug drug reaction Effect Efficacy element eligible enrolled enrolment evening excluded exploratory study generate GMP Government Government of India group hematological hepatic disease HIV HRCT hs-CRP hypersensitivity IgM antibodies IgM antibody illness illnesses immunosuppressive medications Impact impaired cognition index India intensive care intensive care unit Intervention invasive respiratory support journal Laboratory parameters lactating women Level life long term long-COVID malignancy management motor neuron motor neuron disease multiple sclerosis Myocardial infarction negative RT-PCR number objective Open-label open-label design outcome parallel group parameter participant Participants past history Patient Pharmaceutical Company Pittsburgh positive RT-PCR Post-COVID pregnant Previous studies protocol provided pulmonary Pulmonary function test pulmonary tuberculosis Quality Quality of life random randomised randomised controlled trial Randomized Randomized controlled trial recruitment Registered registry rehabilitation renal renal disease respiratory Respiratory disease respiratory distress Respiratory function Safety Sample Sample size SARS CoV SARS CoV-2 SARS-CoV-2 scale Science score secondary Secondary outcomes Sex Shortness of breath Sleep sleep quality SPSS Standard deviation status stroke study duration study group study period Study protocol Subjective substance dependence supplementary material syndrome Tablet the study group timeline Trial Trial registration Tuberculosis Version warm water water website WHO yoga
[DOI] 10.1186/s13063-021-05326-1 PMC 바로가기 [Article Type] Letter

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Research article

Published on 2021-06-012022-10-05
Journal: The Lancet Rheumatology [Category] 임상,

[키워드] 1:1 adverse event analysed assigned benefit C-reactive protein concentration colony stimulating factor Confidence intervals COVID-19 death deaths double-blind enrolled enrolment evaluate finding funding GM-CSF groups hospital hospitalisation hypoxaemia IMPROVE Inflammatory response initiated intention-to-treat population investigator investigator-initiated mechanical ventilation monoclonal antibody multicentre nine no significant difference Odds ratio outcome Oxygen therapy participant Patient patient population patients with COVID-19 Placebo placebo-controlled trial Pneumonia Potential treatment primary endpoint Primary outcome proportion randomised Randomised trial Randomly receive receptor Registered required Research Respiratory failure Seven Severe COVID-19 pneumonia single intravenous infusion Stratification Supplemental oxygen therapy systemic hyperinflammation the placebo group therapy Treatment Trial USA was done were excluded
[DOI] 10.1016/S2665-9913(21)00070-9 [Article Type] Research article

Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations

전염병에 대한 화학 예방 실험 설계: COVID-19 연구 등록에 대한 체계적인 검토에서 얻은 통찰력

Review

Published on 2021-05-292022-09-10
Journal: Trials [Category] SARS, 변종, 치료기술, 치료제,

[키워드] adaptive adaptive design Adaptive platform trial Adults alignment Analysis attack rate attack rates Care Chain Reaction Chemoprophylaxis Chloroquine clinically collaboration component control group coronavirus country COVID-19 COVID-19 vaccines database detect effect size effective Efficacy Efficacy and safety eligibility enrolment Epidemic Epidemics epidemiologically Evidence evidence of exit feasible feature focus followed by General population generate healthcare worker Healthcare workers Hydroxychloroquine implementation Infection Infectious disease Infectious diseases information International IQR less Long-term care Lopinavir Lopinavir/ritonavir mechanism median median size novel vaccines offer Older older adult Older adults pandemic patients polymerase chain reaction Polymerase chain reaction testing PrEP Primary outcome Prophylaxis protocol provided public health randomised Rapid recruitment Registered Repurposed drug Repurposed drugs required Result review Ritonavir robust safety analysis SARS-CoV-2 screened searched Serological testing study population supplementary material Supporting systematic review target population Trial trial infrastructure Trial registration trials utility Vaccine Vaccines virus variants was used were assessed widespread without symptom
[DOI] 10.1186/s13063-021-05323-4 PMC 바로가기 [Article Type] Review

Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial

입원 중인 COVID-19 환자의 회복기 혈장 사용의 안전성과 효능을 평가하기 위한 무작위 임상 시험(PERUCONPLASMA): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-05-172022-09-01
Journal: Trials [Category] SARS, 임상, 진단, 치료기술,

[키워드] 1:1 ABO blood type Acute coronary syndrome administration Adverse reaction Adverse reactions aliquot Aliquots All participants allocation anaphylaxis antibody Antigen assessment Bilirubin Blinding block blocks blood gas blood gas analysis blood type C-reactive protein calculated Capacity carried case report form clinical clinical trial clinical trials Coagulation Coma completion confidence level congestive heart failure contraindication control group convalescent plasma coronary syndrome COVID-19 COVID-19 disease COVID-19 pneumonia creatinine Critical Critical disease CRP current D-dimer decrease defined detect Diagnosis dialysis disease Disseminated intravascular coagulation dissemination Donor donors drop Duration Dynamics eCRF Efficacy electronic case report form element eligible enrolled enrolment etiology evaluate evaluated events Evolution exclusion criteria expected experimental group exploratory failure following gas analysis hemodynamic instability hemorrhage hospital hospital discharge Hospitalization Hospitalized hospitalized patient hospitalized patients Hypothesis Hypoxemia ICU IIb in-hospital mortality Inclusion Infarction Inflammatory information Informed consent intensive care intensive care unit Intervention intracranial hemorrhage intravascular coagulation Invasive mechanical ventilation investigator investigators jaundice Laboratory laboratory confirmation Laboratory test Lactate lactate dehydrogenase Length less Local lymphocyte male marker Mechanical mechanical ventilation mmHg molecular Mortality multi-organ failure Myocardial infarction Neutralizing antibodies number objective occur Older open open label outcome oxygen Oxygen requirement oxygen saturation PaO participant Patient performed plasma Platelets Pneumonia power power of 80% previous diagnosis Probability protocol Public Hospital public hospitals quantification randomization Randomized Randomized controlled trial rationale receive reduce reducing reduction Registered resolution of symptom respiratory respiratory rate routine clinical practice Safe Safety Sample size SARS-COV-2 infection score Secondary objectives serious adverse reaction Serious adverse reactions serologic serum serum creatinine severe COVID-19 Severe COVID-19 pneumonia severe disease SOFA specific type standard treatment standard treatment alone statistical analysis Study protocol Stupor subject supplementary material Total total bilirubin transfusion treatment arm Trial uncontrolled vasopressors Ventilation website with COVID-19
[DOI] 10.1186/s13063-021-05189-6 PMC 바로가기 [Article Type] Letter

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial

초기 SARS-CoV-2 Q-PCR 양성 고위험 개인(RES-Q-HR)의 회복기 혈장/카모스타트 메실레이트: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-05-172022-08-31
Journal: Trials [Category] SARS, 임상, 치료기술, 치료제,

[키워드] accommodation acts Administered administration Adult patients Adverse adverse events alcohol Alcohol Abuse ALT anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anticancer Antiviral antiviral therapy appearance approved AST blinded Blinding BMI body weight Bone marrow Breastfeeding CAD camostat Camostat mesylate Capsule Care Caregivers Cell Child chronic Chronic kidney disease chronic obstructive pulmonary disease chronic obstructive pulmonary disease (COPD) cirrhosis CKD clinical clinical condition Compliance Concomitant concurrent conducted control group Controlled trial convalescent plasma COPD Coronary artery Coronary artery disease cough COVID-19 COVID-19 pneumonia criteria cumulative defined diabetes Diabetes Mellitus diagnosed diagnosis of SARS-CoV-2 diarrhea disease Disease progression disease stage disorder dissemination double-blind Duration early disease Early phase of SARS-CoV-2 infection Efficacy element enrolled Enrollment enrolment EudraCT evaluate evening event evidence of Exanthema excluded exclusion criteria fatigue Fever fibrosis Germany GFR half-live headache high risk higher risk Hospitalization Hospitalized host cell hypersensitivity IgA deficiency immunization Inclusion inclusion criteria increased risk independent individual Infection infection with SARS-CoV-2 Influenza influenza A Informed consent inhibitor institution intervention arm intervention arms Kidney disease less Life expectancy likelihood Liver cirrhosis Local local Ethics Committee Mask mesylate moderate mother multicenter nasal nasal cannula Neutralizing number objective Obstructive obstructive pulmonary disease Older Ordinal Scale organ outcome outcomes oxygen oxygen demand Pancreatitis parallel group participant Participants passive immunization Patient patients hospitalized PCR Placebo plasma Plasma transfusion Pneumonia positive pregnant women Presence Prevent prevent disease progression primary endpoint progression protocol pulmonary disease pulmonary fibrosis Q-PCR randomization Randomized Randomized controlled trial receive recruitment reduce Regulatory reported risk factor safety monitoring committee Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR screening visit Serine serine protease TMPRSS2 Serious Adverse Event Serious Adverse Events severe COVID-19 Shortness of breath SOC sore throat Stage Standard Standard of care stratified Stress Study protocol supplementary material Symptom symptom duration Symptoms tertiary care center tested the cell titers TMPRSS2 transfusion reaction Treatment treatment arm Trial Trial registration Tumor typical symptom typical symptoms ULN virus website WHO with COVID-19 women working hypothesis written Informed Consent
[DOI] 10.1186/s13063-021-05181-0 PMC 바로가기 [Article Type] Letter

A simple cognitive task intervention to prevent intrusive memories after trauma in patients in the Emergency Department: A randomized controlled trial terminated due to COVID-19

Randomized Controlled Trial

Published on 2021-05-102022-10-04
Journal: BMC Research Notes [Category] 임상,

A simple cognitive task intervention to prevent intrusive memories after trauma in patients in the Emergency Department: A randomized controlled trial terminated due to COVID-19

Randomized Controlled Trial

Published on 2021-05-102022-10-27
Journal: BMC Research Notes [Category] COVID-19,

A simple cognitive task intervention to prevent intrusive memories after trauma in patients in the Emergency Department: A randomized controlled trial terminated due to COVID-19

Randomized Controlled Trial

Published on 2021-05-102022-10-27
Journal: BMC Research Notes [Category] Coronavirus, COVID-19, SARS,